J&J seeks FDA's approval for Covid-19 vaccine booster shot in adults

If authorized, J&J's booster could give millions more Americans additional protection against the coronavirus

Johnson & Johnson asked the U.S. Food and Drug Administration to authorize a second dose of its Covid-19 vaccine for adults after a study showed it provided strong protection against infection.

The submission includes results from a late-stage clinical trial that found a booster dose of its one-shot vaccine given 56 days after the first inoculation provided 94% protection against moderate to severe disease in the U.S., the company said in a statement on Tuesday. 

Last week, the FDA said it had scheduled a meeting of its outside scientific advisers to discuss potential boosters for the J&J and Moderna Inc.